HDAC2
Overview
HDAC2 (Histone Deacetylase 2) is a class I histone deacetylase that regulates chromatin structure and gene expression by removing acetyl groups from lysine residues on histone tails. In cancer, HDAC2 plays roles in transcriptional repression and is a target of interest for HDAC inhibitor therapies. Its recurrent mutation in pancreatic ductal adenocarcinoma (PAAD) was identified by MutSigCV analysis, though its precise oncogenic or tumour-suppressive function in that context remains to be validated.
Alterations observed in the corpus
- Identified as a MutSigCV-significant gene in pancreatic ductal adenocarcinoma (PAAD); functional role in PDA biology not yet established — oncogenic vs. passenger status awaits orthogonal validation. PMID:25855536
Cancer types (linked)
- PAAD: Identified as a significantly mutated gene by MutSigCV in a 109-case whole-exome sequencing cohort of resected PDA; listed alongside other novel MutSigCV hits not previously highlighted in pancreatic cancer. PMID:25855536
Co-occurrence and mutual exclusivity
Therapeutic relevance
- No direct therapeutic targeting reported in the corpus. HDAC inhibitors broadly target class I HDACs including HDAC2; specific HDAC2-mutation-driven therapy not reported. PMID:25855536
Open questions
- Whether HDAC2 mutations in PDA are oncogenic drivers or passengers requires functional validation. PMID:25855536
Sources
This page was processed by crosslinker on 2026-05-14.